We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
102 hedge funds and large institutions have $140M invested in Lineage Cell Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 42 increasing their positions, 19 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
121% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 19
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.87% less ownership
Funds ownership: 49.51% → 48.64% (-0.87%)
4% less call options, than puts
Call options by funds: $203K | Put options by funds: $212K
6% less funds holding
Funds holding: 109 → 102 (-7)
7% less capital invested
Capital invested by funds: $151M → $140M (-$11.3M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Holders
102
Holders Change
-7
Holders Change %
-6.42%
% of All Funds
2.54%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
6
Increased
42
Reduced
19
Closed
12
Calls
$203K
Puts
$212K
Net Calls
-$9K
Net Calls Change
+$32K
Top Buyers
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.53M |
| 2 |
Renaissance Technologies
New York
|
+$750K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$678K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$629K |
| 5 |
BC
Broadwood Capital
New York
|
+$453K |
